Frontier Biotechnologies Inc. (SHA:688221)
China
· Delayed Price · Currency is CNY 20.42
+1.20 (6.24%)
At close: Mar 10, 2026
Frontier Biotechnologies Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 143.67 | 125.76 | 110.42 | 83.4 | 40.47 | Upgrade
|
| Other Revenue | - | 3.71 | 3.83 | 1.34 | 0.03 | Upgrade
|
| Revenue | 143.67 | 129.47 | 114.25 | 84.74 | 40.5 | Upgrade
|
| Revenue Growth (YoY) | 10.96% | 13.33% | 34.82% | 109.22% | -13.13% | Upgrade
|
| Cost of Revenue | - | 95.63 | 81.13 | 69.35 | 49.71 | Upgrade
|
| Gross Profit | 143.67 | 33.84 | 33.12 | 15.39 | -9.21 | Upgrade
|
| Selling, General & Admin | - | 171.16 | 159.52 | 135.04 | 136.81 | Upgrade
|
| Research & Development | - | 137.21 | 214.23 | 274.33 | 172.11 | Upgrade
|
| Other Operating Expenses | 405.05 | 4.6 | 3.17 | 2.98 | 1.98 | Upgrade
|
| Operating Expenses | 405.05 | 310.75 | 377.34 | 413.94 | 312.12 | Upgrade
|
| Operating Income | -261.39 | -276.9 | -344.22 | -398.56 | -321.33 | Upgrade
|
| Interest Expense | - | -10.36 | -8.47 | -4.75 | -1.53 | Upgrade
|
| Interest & Investment Income | - | 88.21 | 23.51 | 25.9 | 44.3 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.15 | -3.58 | 0.68 | 0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.33 | -3.05 | -0.91 | -2.03 | -0.48 | Upgrade
|
| EBT Excluding Unusual Items | -261.72 | -201.95 | -333.66 | -378.75 | -278.96 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.08 | -1.06 | -0.25 | 0.72 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.03 | -3.08 | -0.01 | 0 | Upgrade
|
| Asset Writedown | - | -36.65 | -3.22 | - | - | Upgrade
|
| Other Unusual Items | - | 37.16 | 12.05 | 22.25 | 12.97 | Upgrade
|
| Pretax Income | -261.72 | -201.38 | -328.96 | -356.76 | -265.27 | Upgrade
|
| Earnings From Continuing Operations | -261.72 | -201.38 | -328.96 | -356.76 | -265.27 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 5.21 | Upgrade
|
| Net Income | -261.72 | -201.38 | -328.96 | -356.76 | -260.06 | Upgrade
|
| Net Income to Common | -261.72 | -201.38 | -328.96 | -356.76 | -260.06 | Upgrade
|
| Shares Outstanding (Basic) | 374 | 373 | 374 | 364 | 361 | Upgrade
|
| Shares Outstanding (Diluted) | 374 | 373 | 374 | 364 | 361 | Upgrade
|
| Shares Change (YoY) | 0.26% | -0.24% | 2.69% | 0.79% | 25.23% | Upgrade
|
| EPS (Basic) | -0.70 | -0.54 | -0.88 | -0.98 | -0.72 | Upgrade
|
| EPS (Diluted) | -0.70 | -0.54 | -0.88 | -0.98 | -0.72 | Upgrade
|
| Free Cash Flow | - | -191.12 | -396.52 | -429.42 | -570.22 | Upgrade
|
| Free Cash Flow Per Share | - | -0.51 | -1.06 | -1.18 | -1.58 | Upgrade
|
| Gross Margin | 100.00% | 26.14% | 28.99% | 18.16% | -22.74% | Upgrade
|
| Operating Margin | -181.94% | -213.87% | -301.28% | -470.32% | -793.34% | Upgrade
|
| Profit Margin | -182.17% | -155.54% | -287.94% | -421.01% | -642.07% | Upgrade
|
| Free Cash Flow Margin | - | -147.61% | -347.07% | -506.74% | -1407.84% | Upgrade
|
| EBITDA | -240.76 | -256.28 | -301.34 | -352.29 | -283.37 | Upgrade
|
| EBITDA Margin | -167.58% | -197.94% | -263.76% | - | - | Upgrade
|
| D&A For EBITDA | 20.63 | 20.63 | 42.88 | 46.27 | 37.96 | Upgrade
|
| EBIT | -261.39 | -276.9 | -344.22 | -398.56 | -321.33 | Upgrade
|
| EBIT Margin | -181.94% | -213.87% | - | - | - | Upgrade
|
| Revenue as Reported | - | 129.47 | 114.25 | 84.74 | 40.5 | Upgrade
|
| Advertising Expenses | - | 0.52 | 0.31 | 0.09 | 1.13 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.